The metastatic colorectal cancer market is accelerating thanks to advancements in targeted therapies, immuno-oncology, and precision diagnostics. Key players such as Merck, Amgen, and F. Hoffmann-La Roche are leading development of novel treatments and biomarkers. Increasing incidence, improving screening programs, and demand for personalized therapy are pushing growth, while ongoing innovation aims to extend survival and improve quality of life. Access Market Report: https://shorturl.at/d8MXe